Side-by-side comparison of AI visibility scores, market position, and capabilities
SF revenue cycle automation at $99.5M total ($52.5M Oak HC/FT Series C Feb 2025) growing 250% YoY in 2024; claim tracking and AI denial prevention competing with Waystar for digital health and multi-site provider group RCM automation.
Candid Health is a San Francisco-based revenue cycle automation platform — backed with $99.5 million in total funding including a $52.5 million Series C in February 2025 led by Oak HC/FT, following a $29 million Series B in September 2024 led by 8VC — providing healthcare providers with an end-to-end claims automation platform that tracks insurance claims through the full payer adjudication lifecycle, automatically detects and fixes claim errors before and after submission, and provides analytics that improve the touchless claim rate (the percentage of claims that process to payment without any human intervention). Candid Health grew revenue nearly 250% year-over-year in 2024 and is expanding from digital health startups (its initial market) to multi-site provider groups and health systems nationally.
Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.
Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.